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Value of Neoadjuvant Radiation Therapy in
the Management of Pancreatic Adenocarcinoma
William A. Hall, MD1,2; Laura A. Dawson, MD3; Theodore S. Hong, MD4; Manisha Palta, MD5; Joseph M. Herman, MD, MSc, MSHCM6;
Douglas B. Evans, MD2; Susan Tsai, MD, MHS2; Cristina R. Ferrone, MD7; Jason B. Fleming, MD8; Daniel T. Chang, MD9;
Christopher Crane, MD10; Albert C. Koong, MD11; Andrew Oar, MD12; Parag Parikh, MD13; Beth Erickson, MD1,2; Sarah Hoffe, MD8; and
Karyn A. Goodman, MD, MS14

Introduction
Support for the role of neoadjuvant therapy in the
management of nonmetastatic pancreatic adenocarcinoma is growing. With the high risk of rapid dissemination of disease, neoadjuvant therapy allows for
the immediate delivery of systemic therapy to address
micrometastatic disease present in most patients with
localized pancreatic cancer at the time of diagnosis.
This strategy will increase the number of patients who
receive systemic therapy, since only approximately
50% of patients are able to receive a full course of
chemotherapy after surgery.1-4 Moreover, 2-4 months
of neoadjuvant therapy provides a window to identify
those patients who will develop early distant metastases. This selects patients with more favorable disease courses who may beneﬁt from surgery, thus
sparing patients with unfavorable tumor biology from
undergoing a large surgical intervention. Such treatment sequencing is important and likely improves the
overall survival (OS) of the entire population of affected
patients.5-8 However, the optimal neoadjuvant regimen
has not been established.
The use of radiation therapy (RT) as a component of
neoadjuvant therapy has been evaluated in several
recent studies with conﬂicting results.5,9 These studies
have used various RT doses and modalities, making
the existing data difﬁcult to interpret across studies.
Given the lack of deﬁnitive data and potential concerns
about quality assurance when using newer RT modalities in patients with pancreatic cancer, the jury is
still out as to the role of RT in the preoperative treatment of borderline resectable pancreatic cancer. In
this commentary, we contend that there is strong rationale for continuing to study and reﬁne the role of
neoadjuvant RT for patients with pancreatic cancer, a
disease where improvements in OS have been modest
over the past four decades.
Surgery First Approach
Up-front surgical resection for resectable pancreatic
cancer remains a standard that has been debated for
over a decade. When patients undergo surgery ﬁrst,

the rate of positive margins range from 30% to 50% and
local recurrence events range from 20% to 50%.10
These event rates are ﬁve times higher than other
types of adenocarcinoma treated with up-front surgical
resection.11,12 Although improving OS outcomes have
been reported for patients who have successfully
completed up-front surgical resection and adjuvant
chemotherapy,13 these OS data are at least partially
driven by intense biological selection. Speciﬁcally, these
outcomes are enriched by the inclusion of patients who
withstood the challenges associated with surgical resection, recovery, postoperative restaging, and enrollment into a clinical trial. This timing of enrollment
selects for patients without early disease progression on
postoperative imaging. Biological selection, driven by
surgery ﬁrst (in sharp contrast to systemic therapy ﬁrst),
is not a strategy to meaningfully improve the OS of all
patients with localized pancreatic cancer.
It is clear that the survival outcomes reported in adjuvant trials that enroll after postoperative restaging are
not seen in patients who are enrolled and randomly
assigned before surgical resection. As clear testament
to this, the recently published SWOG 1505 trial (which
enrolled patients with resectable disease before surgery) observed a median OS of 23.2 months using
modiﬁed folinic acid, ﬂuorouracil, irinotecan, and
oxaliplatin (mFOLFIRINOX) perioperatively, whereas
the PRODIGE-24-ACCORD trial, enrolling patients
after surgery and recovery (again using mFOLFIRINOX
adjuvantly), demonstrated a median OS of 54 months.1,13
Does this mean that the best patient outcomes are
achieved with a surgery ﬁrst approach followed by
adjuvant chemotherapy? No, to the contrary, a surgery
ﬁrst and adjuvant chemotherapeutic approach leaves
meaningful numbers of patients excluded from the
beneﬁts of multimodality therapy. Patients who do not
recover adequately from surgery, are incompletely
resected, or develop early disease recurrence are
never eligible for protocol enrollment. In other words,
those patients with the worst outcomes are excluded
from enrollment to such trials. For this reason, these
results cannot be compared with outcomes in trials
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that enrolled patients before surgery or immediately after
diagnosis. Optimal methods to evaluate the efﬁcacy of novel
therapies in patients diagnosed with pancreatic adenocarcinoma are most likely to be found by enrolling patients
at the time of diagnosis/staging and examining patient
outcomes with an intention-to-treat analysis.
Neoadjuvant Therapy
There have been several recent prospective trials that have
examined neoadjuvant therapy as compared with surgery
ﬁrst. It is becoming more apparent that neoadjuvant
therapy for patients with localized pancreatic cancer improves OS when compared with surgery ﬁrst.5-8 Although
neoadjuvant therapy has shown considerable promise, the
optimal regimen remains unclear. This lack of clarity is
secondary to a paucity of randomized neoadjuvant trials.
Whether chemotherapy alone or combinations of systemic
chemotherapy and RT should be used, along with optimal
dose, fractionation, and sequencing of these modalities
remains unknown. It needs to be recognized that there is a
near complete absence of well-powered, randomized trials
that have met their initial accrual goals, robustly evaluating
the utility (or absence of utility) for RT. The absence of such
data limits conclusions that can be drawn comparing
therapeutic interventions, leaving physicians to rely on
single-institution and retrospective reports of different
neoadjuvant regimens.
There have been numerous prospective, nonrandomized,
phase II trials that have examined different types of neoadjuvant therapy for pancreatic adenocarcinoma.14-17 It is
important to recognize that nearly all these trials have included some type of concurrent chemotherapy and fractionated RT (CRT). Several have been conducted at single
centers, which limits their generalizability as the supportive
care provided to patients with pancreatic cancer greatly
affects the successful receipt of all intended therapy.18 A
few multicenter, prospective studies have examined the
role of neoadjuvant therapy (including CRT) compared with
up-front surgery. As an example, Jang et al reported the
results of a multicenter phase II/III trial evaluating neoadjuvant CRT followed by surgery or up-front surgery followed by the same CRT regimen. This randomized study
was terminated early by the safety-monitoring committee
after 58 patients were enrolled demonstrating a median OS
in the neoadjuvant CRT arm of 21 months versus
12 months in the up-front surgery arm (P 5 .028). The R0
resection rate was also signiﬁcantly improved with neoadjuvant CRT (51.8% v 26.1%; P 5 .004).8 A second
example is the recent PREOPANC randomized trial that
compared neoadjuvant CRT, with concurrent gemcitabine
and 36 Gy in 15 fractions followed by surgery, with up-front
surgery followed by adjuvant gemcitabine. This study did
not show an OS beneﬁt in the intent-to-treat analysis in the
initial manuscript publication,19 but a more recent updated
abstract demonstrated an OS improvement in the neoadjuvant arm.5 The neoadjuvant CRT arm was associated

with an improved R0 resection rate (71% v 40%; P , .001),
a lower rate of node positivity (78% v 33%; P , .001), and
an improved disease-free survival (8.1 v 7.7 months;
P 5 .03).19 Of note, when the preplanned subgroup of 120
patients who underwent successful surgery was analyzed,
there indeed was a signiﬁcant improvement in median OS
with neoadjuvant CRT (35.2 v 19.8 months; P 5 .029).
Although the full manuscript on these updated data is
anticipated, it seems clear that neoadjuvant chemotherapy
and RT improved OS.5 What is not clear is if chemotherapy
alone would have accomplished these same results. Exemplifying this uncertainty is the recently published
SWOG1505 study of neoadjuvant chemotherapy alone
(FOLFIRINOX v gemcitabine/nab-paclitaxel perioperatively), without RT, demonstrating a median OS of approximately 23.5 months in patients with resectable
disease. There were no differences in response between
FOLFIRINOX and gemcitabine/nab-paclitaxel. These
modest OS outcomes in resectable disease suggest that
chemotherapy alone may not be adequate for these patients.1 Another recently reported neoadjuvant study was
ESPAC-5F. This was a four-arm, multicenter phase II trial
evaluating different methods of neoadjuvant therapy for
patients with borderline resectable pancreatic cancer.
Ninety patients were randomly assigned to receive immediate surgery or neoadjuvant therapy consisting of either
two cycles of gemcitabine/capecitabine or four cycles of
FOLFIRINOX or 50.4-Gy capecitabine-based CRT in 28
fractions.7 The 1-year OS rate was 40% for immediate
surgery and 77% for neoadjuvant therapy (P , .001).
There was minimal power to cross compare groups on this
study given the small numbers.7 Taken together, these
studies suggest that neoadjuvant therapy likely improves
OS in patients with localized, operable pancreatic cancer;
however, the optimal method of delivery remains unknown.
With this magnitude of data including CRT, this would
certainly suggest that RT is worthy of further investigation.
Despite this, multiple neoadjuvant phase III trials have
moved forward omitting RT entirely in pancreatic cancer
(NCT03941093, NCT04340141, and NCT04617821), and
National Comprehensive Cancer Network guidelines lack
consensus as to the role of RT, reporting it as a consideration or as plus/minus.20
Neoadjuvant Stereotactic Body Radiation Therapy
There have been no prospective trials in pancreatic cancer
directly comparing different RT strategies such as CRT or
stereotactic body radiation therapy (SBRT). There have
been multiple single-institution retrospective and prospective studies evaluating neoadjuvant SBRT for borderline and locally advanced pancreatic cancer (LAPC)
demonstrating excellent R0 resection rates and promising
OS.21,22,24 These retrospective single-institutional reports
are limited by selection bias, yet none of these series
yielded a detriment to R0 resection associated with SBRT.
Sharply conﬂicting with these results is the recent Alliance
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randomized trial, A021501, that introduced SBRT to a
multi-institutional National Clinical Trials Network (NCTN)
study group. Unfortunately, this strategy was associated
with low rates of pancreatectomy (35%) and treatment
completion (18%).9 Importantly, the use of SBRT deviated
from the initial predicate of the Alliance A021101 feasibility
study, which delivered historic and time-tested fractionated
CRT. This approach had resulted in 68% of patients going
on to surgical resection, of whom 93% (who went to surgery) had an R0 resection.25 The reason for the critical
differences in RT administration across these trials was
multifactorial. This was partly based on the absence of
beneﬁt of low-dose fractionated RT and chemotherapy on
the LAP-07 trial,26 expert consensus from the committee
designing the trial, and early data indicating favorable results with neoadjuvant SBRT. However, widely integrating
FOLFIRINOX, SBRT, and surgery at multiple centers with
limited experience using this approach was likely premature. Moreover, the original A021101 study was performed
in a limited number of high-volume pancreatic cancer
centers without an adaptive design; patients received
2 months of chemotherapy followed by CRT. Such highvolume centers had extensive multidisciplinary experience
with neoadjuvant therapy in pancreatic cancer. It is also
notable that other publications of neoadjuvant SBRT, in
single-institution settings, yielded much higher R0 resection rates and better survival outcomes.21,22,24 One such
example is from the University of Colorado that demonstrated that among 103 patients with locally advanced
(n 5 18) or borderline resectable disease (n 5 85) who
received neoadjuvant chemotherapy followed by SBRT, 73
underwent deﬁnitive surgery and the R0 resection rate was
69% (97% in those who underwent surgery).22 There are
potential concerns about the appropriate volume for pancreas SBRT; speciﬁcally, smaller volumes are associated
with the potential for marginal misses that could contribute
to local recurrences, at either the celiac trunk or near the
take-off of the superior mesenteric artery.23,27 The A021501
trial illustrates the challenges of introducing an adaptive
trial design and delivering SBRT followed by complicated
surgeries across the NCTN. It appears that the introduction
of SBRT may have been prematurely applied in this setting.
Lower resection rates may also be in part because of the
lack of experience with major pancreatic surgery after
SBRT. Therefore, such a result should not be interpreted as
closing the door on the potential beneﬁts of RT, such as
fractionated CRT, or magnetic resonance-guided adaptive
SBRT, given after induction chemotherapy in the neoadjuvant setting. We simply do not understand the best type
of neoadjuvant therapy. The only method to generate such
understanding is additional, well-powered clinical trials.
The wide spectrum of RT modalities and delivery methods
present a challenge when implementing such a treatment
across a network of hospitals such as that in the NCTN.
Compliance with RT treatment plans has been shown to

potentially affect OS, speciﬁcally as it relates to the use of
RT in pancreatic cancer trials, although this point is
controversial.28,29 If centers are less familiar with a speciﬁc
RT approach, any complications in the neoadjuvant course
can derail the treatment plan and negatively affect the
ultimate goal of a grossly complete surgical resection. As
more advanced RT modalities emerge, quality control remains of the utmost importance across the trajectory of
care.29
Future Directions
The role of RT in the neoadjuvant setting has not been fully
vetted. Current studies do not provide deﬁnitive answers as
to how this modality should be applied to patients with
borderline resectable pancreatic cancer. Excluding a potentially highly effective modality, in the absence of wellpowered randomized data, is not a strategy to improve
outcomes for patients with pancreatic cancer. Welldesigned prospective studies that include adequate realtime quality assurance for the RT, have standards for
deﬁning resectability, and are powered to evaluate
meaningful outcomes across therapy strategies are
needed. The anticipated PREOPANC-II study (NTR7292)
is comparing neoadjuvant FOLFIRINOX with neoadjuvant
gemcitabine-based CRT for patients with borderline resectable pancreatic cancer; however, this study does not
evaluate the addition of CRT after FOLFIRINOX and is still
unlikely to fully clarify the true role of RT. There are other
ongoing trials that will help in this regard. One such example is the MASTERPLAN study (NCT04089150), which
is evaluating the addition of SBRT to FOLFIRINOX chemotherapy in operable, borderline resectable, and LAPC.
This trial mandates central SBRT plan storage with realtime QA, in addition to central radiology review, and is likely
to offer some further insight into the role of SBRT in patients
with potentially operable and LAPC. A second example is
the SOFT study (NCT03704662), which randomly assigns
patients to either SBRT or fractionated CRT-based therapy
(50.4-Gy in 28 fractions with concurrent gemcitabine) after
neoadjuvant chemotherapy and before surgical resection.
Without appropriate study designs, ideally randomized, we
are not able to move beyond the fundamental question of
the role of RT. We also cannot evaluate additional novel
questions such as how to incorporate more sophisticated
technologic advances and combinations of RT and novel
concurrent agents. The methods for delivering RT and
achieving tumor ablation while reducing the risk of toxicity
are rapidly evolving.30 One example is real-time magnetic
resonance guidance, which offers an unparalleled ability to
visualize normal organs in close proximity to a tumor. Novel
methods of radiosensitization and radioprotectors are also
continuing to emerge, and RT may be important as an
immunomodulator, something that could potentially dramatically transform the treatment of pancreatic cancer.31-33
We are only beginning to understand the incredible capabilities of RT and we simply cannot allow it to be absent
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from routine consideration and robust prospective
evaluation.34
In conclusion, prospective trials comparing different neoadjuvant management strategies are needed in pancreatic
adenocarcinoma. Novel RT strategies should be reﬁned
and robustly evaluated prospectively to potentially improve
outcomes in this devastating malignancy. Moreover, these
studies will help to better deﬁne which patients are most
likely to beneﬁt from the incorporation of RT and which type
of RT is most appropriate in different clinical scenarios. On
the basis of existing prospective data, CRT should routinely
be considered in the neoadjuvant management of pancreatic adenocarcinoma. Importantly, any local therapy
(surgery or RT) will beneﬁt only the subset of patients who
successfully navigate the gauntlet of early systemic failure;
this subset will continue to increase as systemic therapies
improve. Therefore, rational and well-conducted studies, in

which meaningful numbers of patients complete therapy,
are critical to adequately evaluate the role of RT in the
management of localized pancreatic adenocarcinoma.
Going forward, a robust neoadjuvant study would ideally
compare preoperative chemotherapy alone versus preoperative chemotherapy followed by CRT or hypofractionated
RT/SBRT and incorporate clear criteria for resectability,
assessment of intraoperative margins, and central review of
all postoperative imaging for accurate assessment of patterns of recurrence. Pretreatment credentialing of sites and
real-time QA for all RT planning is essential for the results of
such a trial. We must continue to partner together in a
multidisciplinary setting, focus on forming a better foundation of randomized data on which to draw reliable
conclusions, and develop the ideal armamentarium to
optimally treat patients with this challenging disease.
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